TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03052244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS+VI
Description: 2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS Sham+VI Sham
Description: 2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
Study: NCT05958797

Intervention type: DRUG
Intervention: Chloroquine
Description: Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance

Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study: NCT02305212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Study: NCT03235947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim / Sulfamethoxazole
Description: Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim / Sulfamethoxazole
Description: Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous placebo
Description: Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
Study: NCT03813264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine outcome measures (ROM)
Description: The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
Study: NCT03840707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFEwithIBD
Description: LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease
Study: NCT02885246

Intervention type: OTHER
Intervention: Data collection
Description: The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
Study: NCT03399630

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of Autologous Adipose Tissue
Description: Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injection of lactated ringers
Description: Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
Study: NCT00183326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-centered supportive therapy (CCT)
Description: CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
Study: NCT04086914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
Study: NCT00934219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-Acid Ethyl Esters
Description: LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-Acid Ethyl Esters
Description: LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
Study: NCT00802152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home monitoring
Description: The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
Study: NCT04668066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07242813
Description: PF-07242813 given intravenously or subcutaneous
Study: NCT01525615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat inhaler
Description: Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol (low dose)
Description: 2.5 µg tiotropium + 5 µg olodaterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol (high dose)
Description: 5 µg tiotropium + 5 µg olodaterol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat inhaler
Description: Respimat inhaler

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat inhaler
Description: Respimat inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to tiotropium+olodaterol
Description: comparator
Study: NCT03831100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHT
Description: The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Control
Description: AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session (Table 5) is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
Study: NCT00826618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
Study: NCT04668066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07242813
Description: PF-07242813 given intravenously or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07242813
Description: PF-07242813 given intravenously or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously or subcutaneous
Study: NCT01107665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib and Paclitaxel
Description: Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
Study: NCT03325959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBOT) treatment
Description: 60 HBOT sessions at 2 ATA 100% oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta / Lyrica treatment
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossover Hyperbaric oxygen therapy
Description: 60 HBOT sessions at 2 ATA 100% oxygen after crossover
Study: NCT01103388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
Study: NCT04499560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement Drink
Description: Superfoods based nutritional supplement
Study: NCT03609411

Intervention type: PROCEDURE
Intervention: Splenectomy
Description: Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
Study: NCT03060200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered online CBT plus therapist check in
Description: The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham self-administered online CBT plus therapist check in
Description: The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
Study: NCT00665535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Turning or repositioning schedule
Description: Turning schedule randomly assigned at 2, 3, or 4 hours
Study: NCT04668066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously or subcutaneous
Study: NCT01097174

Intervention type: DEVICE
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
Study: NCT01530776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Group
Description: Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
Study: NCT00949624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 75 mg/m2 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 100 mg BID continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 100 mg/m2 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-868,596
Description: Oral tablet 60 mg BID continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Oral tablet 5 mg BID continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous 75 mg/m2 every three weeks
Study: NCT02733510

Intervention type: DRUG
Intervention: methylprednisolone
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
Study: NCT00706836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 50mg
Description: One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 200 MG
Description: One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One dose of matched oral placebo to be administered one hour prior to fMRI scan
Study: NCT00544076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprostadil
Description: Given intraurethrally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic surgery
Description: Undergo prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopic surgery
Description: Undergo prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted laparoscopic surgery
Description: Undergo prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00889863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
Study: NCT04554615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin infusion to control postoperative hyperglycemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin infusion to control postoperative hyperglycemia
Study: NCT00665535

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Turning or repositioning schedule
Description: Turning schedule randomly assigned at 2, 3 or 4 hours
Study: NCT03406780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAP-1002
Description: The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
Study: NCT00962325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to increase physical activity
Description: This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
Study: NCT00978146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
Study: NCT01325688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluminium disk

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OpSite(TM) disk
Study: NCT00544076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02279095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 1
Description: Palovarotene was taken orally once daily at approximately the same time each day.
Study: NCT00544076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02279095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 2
Description: Palovarotene will be taken orally once daily at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 3
Description: Palovarotene will be taken orally once daily at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene dose level 4
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Study: NCT03475485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Capsule- Active
Description: A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader
Study: NCT03406780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03475485

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
Study: NCT04205682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: CBD capsules administered BD for 4-days (800-1200 mg/day), placebo day 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered BD for 5 days
Study: NCT00881348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd infantile (Lactic Acid)
Study: NCT03487744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite 1.5
Description: Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promote without fiber
Description: Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
Study: NCT03949608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning
Description: The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it.
Study: NCT03517761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate treatment
Description: While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
Study: NCT03181399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: . Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.